GlassScriptPhysician profile
Mark R Jones
NPI 1477559490
$5,590.46
in general payments reported to CMS, 2019-2025
45 companies · $41.95 in 2025
The $41.95 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,131 · 2020: $958 · 2021: $322 · 2022: $617 · 2023: $769 · 2024: $752 · 2025: $41.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $765.56 | 2019-2024 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $612.04 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $466.76 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $341.01 | 2019-2024 | Mounjaro, Trulicity, Baqsimi |
| Abbott Laboratories | $340.22 | 2021-2025 | Freestyle Libre |
| Pfizer INC. | $335.98 | 2019-2024 | |
| Glaxosmithkline, LLC. | $257.37 | 2019-2024 | Shingrix, Arexvy, Flulaval Quadrivalent |
| Sunovion Pharmaceuticals INC. | $245.86 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $179.82 | 2019-2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $161.27 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.67 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $143.22 | 2019-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Abbvie INC. | $115.62 | 2021-2024 | |
| Amarin Pharma, INC. | $108.59 | 2020-2021 | |
| Boston Scientific Corporation | $105.27 | 2019 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.